Theodore Wing

Dec 13, 2023 | biorxiv.org | Christopher Price |Dylan Stavish |Owen Laing |Theodore Wing

AbstractHuman pluripotent stem cell (hPSC)-derived cardiomyocytes have emerged as powerful tools for disease modelling and cell therapy. The production of cardiomyocytes from hPSCs typically requires expanding large numbers of hPSCs and maintaining them in culture for extended periods of time. This in turn predisposes hPSCs to the acquisition of non-random genetic changes, including recurrent gains of chromosome 1q.